Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32575454 | 1.00 | IDO1 (0.55) | IDO1CA12CA14CA2MMP2 | |
| SCHEMBL9162775 | 0.86 | IDO1 (0.63) | IDO1CA12CA14CA2MMP2 | |
| SCHEMBL18351225 | 0.84 | CA12 (0.53) | IDO1CA12CA14CA2MMP2 | |
| SCHEMBL11336488 | 0.83 | CA12 (0.56) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL3232676 | 0.83 | CA12 (0.51) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL3725975 | 0.83 | CA12 (0.51) | CA12CA14CA2MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL27787241 | 0.82 | CA12 (0.50) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL17836961 | 0.81 | ALDH1A1 (0.65) | IDO1CA12CA14CA2MMP2 | |
| SCHEMBL7567033 | 0.80 | CA12 (0.53) | CA12CA14CA2MMP2MMP9 | |
| SCHEMBL9987427 | 0.80 | CA12 (0.49) | IDO1CA12CA14CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4685176-A1 | 2-COMPONENT FOAMS BASED ON ACETYLACETONATE AND AMINES | Henkel AG & Co. KGaA (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2024102458-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| EP-1971664-B1 | EMITTING MATERIALS AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | LG CHEMICAL LTD (KR) | 2015-09-09 | — | — | EP | claimed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | KANSAL VINOD K | 2008-02-21 | — | — | US | claimed |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | TEVA PHARMACEUTICAL USA, INC. | 2007-08-16 | — | — | US | claimed |
| WO-2007081179-A1 | EMITTING MATERIALS AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME | LG CHEM. LTD. (KR) | 2007-07-19 | — | — | WO | claimed |
| EP-1802568-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-04 | — | — | EP | claimed |
| WO-2007035789-A1 | CHIRAL 3-CARBAMOYLMETHYL-5-METHYL HEXANOIC ACIDS, KEY INTERMEDIATES FOR THE NEW SYNTHESIS OF (S)-PREGABALIN | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-03-29 | — | — | WO | claimed |
| US-20070037012-A1 | having an anthracene compound substituted with at least one thiophenyl ring; OLED organic light emitters; as displays with low power consumption, faster response time, higher brightness level, unlimited viewing angle | LG CHEM, LTD. (KR) | 2007-02-15 | — | — | US | claimed |
| EP-1501821-A1 | NEW ORGANIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMINESCENT DEVICES USING THE SAME | LG Chem, Ltd. (KR) | 2005-02-02 | — | — | EP | claimed |
| CN-1556803-A | Novel organic compound for electroluminescence and organic electroluminescent device using the same | LG��ѧ��ʽ���� | 2004-12-22 | — | — | CN | claimed |
| US-20040067387-A1 | Organic compounds for electroluminescence and organic electroluminescent devices using the same | LG CHEM. LTD. (KR) | 2004-04-08 | — | — | US | claimed |
| WO-2003095445-A1 | NEW ORGANIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMINESCENT DEVICES USING THE SAME | LG CHEM, LTD. (KR) | 2003-11-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045747-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin | GABRE, GABRA5, GABRA6 | IDO1 1850/4885CA12 1786/4885CA14 2305/4885 |
| US-20070191636-A1 | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin | GABRE, GABRA5, GABRA6 | IDO1 1850/4885CA12 1786/4885CA14 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.